Quantum Leap Healthcare Collaborative
search
Agents & Results

Agent Information

The I-SPY Program is committed to open science, through timely publication and release of results, and ultimately data, from all arms of our trials.
Close
Close
I-SPY Trial Manuscript
Close
Close
Close
Close
I-SPY People
Close
Close
<- Back to All Agents

pembrolizumab (8 cycles)

Trade Name:
Keytruda
Company:
Merck
Status:
Completed (Results Pending)
Agent Chaperone(s):
Minetta LiuPatricia Robinson
Treatment Protocol:
Pembrolizumab is a PD-1 Inhibitor. The dose regimen is as follows: Paclitaxel (q1w × 12 weeks) and pembrolizumab (q3w ×24 weeks).Option only for participants enrolled before Feburary 9th 2018, paclitaxel (q1w x 12 weeks) + pembrolizumab (q3w x 12 weeks); followed by AC + pembrolizumab (q3w x 12 weeks). Cycles 13,14,15 and 16 are given as AC + pembrolizumab combination every 3 weeks.
Date Entered I-SPY:
July 21, 2017
Date Left I-SPY:
No. Participants in Arm:
Graduating Subtypes:
Agent Description:

Pembrolizumab (Keytruda) is a humanized antibody used in cancer immunotherapy. It is an IgG4 isotype antibody that blocks a protective mechanism of cancer cells, and allows the immune system to destroy those cancer cells. It targets the programmed cell death 1 (PD-1) receptor of lymphocytes.The "pembro8" arm of the study is evaluating 8 cycles of pembrolizumab treatment, as opposed to 4 cycles in the previously evaluated arm.

Notes:
Final pCR Probabilities:
Primary Manuscript:
, 
. 
 
: 
, 
. 
abstractpdfdoi link

The I-SPY Trials

Sponsored by Quantum Leap Healthcare Collaborative™, a 501C(3) charitable organization accelerating the union of high-impact clinical research and patient care to improve and save lives.

 
Quick Links:
Media CenterCareersInvestigator Login
© 2019  Quantum Leap Healthcare Collaborative